Rebyota, a Microbiota-Based Live Biotherapeutic, (fecal microbiota, live-jslm) has been approved for the prevention of recurrence of Clostridioides Difficile Infection in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

• Ferring’s novel first-in-class Rebyota is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI
• The safety and efficacy of Rebyota was studied in the largest clinical trial program in the field of microbiome-based therapeutics, including five clinical trials with more than 1,000 participants
• Recurrent CDI represents a significant burden for patients, caregivers and the healthcare system.
• Read more… https://www.drugs.com/newdrugs/fda-approves-rebyota-fecal-microbiota-live-jslm-microbiotabased-live-biotherapeutic-prevention-5934.html